Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2857916 with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT03715478Phase 2Active, not recruiting
- Sponsor
- Canadian Myeloma Research Group
- Start
- Nov 2018
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by Canadian Myeloma Research Group. Started Nov 2018; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03715478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715478.